FindTrial
Sign In

Risk stratification of prognosis in AFP-negative hepatocellular carcinoma by integrating elevated preoperative PIVKA-II and CA19-9

Effect of tumor markers related to hepatocellular carcinoma on prognosis after hepatocellular carcinoma resection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052310
Enrollment
Unknown
Registered
2021-10-24
Start date
2021-10-26
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

grouped according to the comprehensive score of tumor marker value:N/A

Sponsors

Sun Yat-Sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with HCC were screened between January 2016 and December 2019 who underwent curative-purpose liver resection as initial therapy. All patients had resectable tumors, normal liver function, no extrahepatic metastasis, and were aged 18-80 years.

Exclusion criteria

Exclusion criteria: 1. Preoperative AFP level >20 ng/ml; 2. Preoperative serum total bilirubin value>2.0 ml/dl; 3. Child-Pugh B or C liver function; 4. Non-r0 liver resection, including microscopically positive (R1) or microscopically positive (R2) margins; 5. Pathological diagnosis of hepatocellular carcinoma and cholangiocarcinoma combined; 6. Incomplete clinical data for important medical information.

Design outcomes

Primary

MeasureTime frame
overall survival;—

Secondary

MeasureTime frame
progression-free survival;time to early recurrence;—

Countries

China

Contacts

Public ContactGuo Rongping

Sun Yat-Sen University Cancer Center

meijie@sysucc.org.cn+86 15363732185

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026